HC Wainwright restated their buy rating on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) in a research report released on Friday, November 10th. The brokerage currently has a $6.00 price objective on the biopharmaceutical company’s stock.
Several other equities analysts have also commented on CPRX. Piper Jaffray Companies set a $6.00 price objective on Catalyst Pharmaceuticals and gave the company a buy rating in a research report on Monday, August 7th. Roth Capital set a $5.00 price target on Catalyst Pharmaceuticals and gave the stock a buy rating in a research report on Thursday, August 10th. SunTrust Banks restated a buy rating and set a $5.00 price target on shares of Catalyst Pharmaceuticals in a research report on Tuesday, September 5th. Finally, Zacks Investment Research lowered Catalyst Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, October 11th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $5.75.
Catalyst Pharmaceuticals (NASDAQ:CPRX) traded down $0.01 during trading hours on Friday, hitting $3.97. The company’s stock had a trading volume of 1,667,600 shares, compared to its average volume of 944,284. Catalyst Pharmaceuticals has a 1 year low of $1.01 and a 1 year high of $4.07.
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Nationwide Fund Advisors purchased a new position in shares of Catalyst Pharmaceuticals in the 2nd quarter valued at approximately $111,000. New York State Common Retirement Fund purchased a new position in shares of Catalyst Pharmaceuticals in the 2nd quarter valued at approximately $114,000. Bank of New York Mellon Corp lifted its stake in shares of Catalyst Pharmaceuticals by 3.6% in the 1st quarter. Bank of New York Mellon Corp now owns 69,176 shares of the biopharmaceutical company’s stock valued at $135,000 after purchasing an additional 2,404 shares during the period. SG Americas Securities LLC purchased a new position in shares of Catalyst Pharmaceuticals in the 3rd quarter valued at approximately $144,000. Finally, State of Wisconsin Investment Board purchased a new position in shares of Catalyst Pharmaceuticals in the 2nd quarter valued at approximately $149,000. Institutional investors own 41.31% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/catalyst-pharmaceuticals-inc-cprx-given-buy-rating-at-hc-wainwright/1775319.html.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.